The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
Top Cited Papers
Open Access
- 15 October 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-15
Abstract
A priority in cancer research is to innovate therapies that are not only effective against tumor progression but also address comorbidities such as cachexia that limit quality and quantity of life. We demonstrate that TLR7/8 agonist R848 induces anti-tumor responses and attenuates cachexia in murine models of pancreatic ductal adenocarcinoma (PDAC). In vivo, tumors from two of three cell lines were R848-sensitive, resulting in smaller tumor mass, increased immune complexity, increased CD8+ T-cell infiltration and activity, and decreased Treg frequency. R848-treated mice demonstrated improvements in behavioral and molecular cachexia manifestations, resulting in a near-doubling of survival duration. Knockout mouse studies revealed that stromal, not neoplastic, TLR7 is requisite for R848-mediated responses. In patient samples, we found Tlr7 is ubiquitously expressed in stroma across all stages of pancreatic neoplasia, but epithelial Tlr7 expression is relatively uncommon. These studies indicate immune-enhancing approaches including R848 may be useful in PDAC and cancer-associated cachexia.Keywords
Funding Information
- EIF | Stand Up To Cancer (SU2C-AACR-DT14-14)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA217989-01, R01CA184324-01)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- Brenden-Colson Center for Pancreatic Care
This publication has 61 references indexed in Scilit:
- TLR8: the forgotten relative revindicatedCellular & Molecular Immunology, 2012
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2012
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancerJournal of Experimental Medicine, 2011
- Similar Structures but Different Roles – An Updated Perspective on TLR StructuresFrontiers in Physiology, 2011
- Cachexia as a major underestimated and unmet medical need: facts and numbersJournal of Cachexia, Sarcopenia and Muscle, 2010
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- The Immunological Genome Project: networks of gene expression in immune cellsNature Immunology, 2008
- UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomesNature, 2008
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848Nature Immunology, 2002